Posts tagged roughness
Fibrocell Phase 2 vocal scaring trial fails

A Phase 2 clinical trial of Fibrocell Science’s (NASDAQ:FCSC) azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia failed to meet its primary endpoints.

Fibrocell intends to focus its efforts on the development of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa and its earlier-stage programs.

Read More